TABLE 8.3-continued

mAb 2 Top Titers AA, AL, AM, AV, GF, GL, GT, SA, ST Top Tm AI, AV, GI, SI, GV (low titers we observed with HC: 56 H and M)

REFERENCES

- [0227] Bentley D R, Balasubramanian S, Swerdlow H P, Smith G P, Milton J, et al. 2008. Accurate whole human genome sequencing using reversible terminator chemistry. *Nature* 456: 53-9
- [0228] Branton D, Deamer D W, Marziali A, Bayley H, Benner S A, et al. 2008. The potential and challenges of nanopore sequencing. *Nat Biotechnol* 26: 1146-53
- [0229] Durocher Y, Perret S, Kamen A. 2002. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. *Nucleic Acids Res* 30: E9
- [0230] Eid J, Fehr A, Gray J, Luong K, Lyle J, et al. 2009. Real-time DNA sequencing from single polymerase molecules. *Science* 323: 133-8
- [0231] Engler C, Gruetzner R, Kandzia R, Marillonnet S. 2009. Golden gate shuffling: a one-pot DNA shuffling method based on type IIs restriction enzymes. *PLoS One* 4: e5553
- [0232] Engler C, Kandzia R, Marillonnet S. 2008. A one pot, one step, precision cloning method with high throughput capability. *PLoS One* 3: e3647
- [0233] Fahrner R L, Knudsen H L, Basey C D, Galan W, Feuerhelm D, et al. 2001. Industrial purification of pharmaceutical antibodies: development, operation, and validation of chromatography processes. *Biotechnol Genet* Eng Rev 18: 301-27
- [0234] Honegger A, Pluckthun A. 2001. Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool. *J Mol Biol* 309: 657-70
- [0235] Jafari R, Alnnqvist H, Axelsson H, Ignatushchenko M, Lundback T, et al. 2014. The cellular thermal shift assay for evaluating drug target interactions in cells. *Nat Protoc* 9: 2100-22
- [0236] Kamerzell T J, Esfandiary R, Joshi S B, Middaugh C R, Volkin D B. 2011. Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development. Adv Drug Deliv Rev 63: 1118-59
- [0237] Kelley B. 2009. Industrialization of mAb production technology: the bioprocessing industry at a crossroads. *MAbs* 1: 443-52
- [0238] Kostelny S A, Cole M S, Tso J Y. 1992. Formation of a bispecific antibody by the use of leucine zippers. *J Immunol* 148: 1547-53
- [0239] Lo M C, Aulabaugh A, Jin G, Cowling R, Bard J, et al. 2004. Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. *Anal Biochem* 332: 153-9
- [0240] Makhatadze G. 1998. Measuring protein thermostability by differential scanning calorimetry. *Curr. Protocols Protein Sci.* 12: 7.9.1-7.9.14

- [0241] Margulies M, Egholm M, Altman W E, Attiya S, Bader J S, et al. 2005. Genome sequencing in microfabricated high-density picolitre reactors. *Nature* 437: 376-80
- [0242] Mason M, Sweeney B, Cain K, Stephens P, Sharfstein S T. 2012. Identifying bottlenecks in transient and stable production of recombinant monoclonal-antibody sequence variants in Chinese hamster ovary cells. *Bio*technol Prog 28: 846-55
- [0243] Medzihradszky K F, Chalkley R J. 2015. Lessons in de novo peptide sequencing by tandem mass spectrometry. *Mass Spectrom Rev* 34: 43-63
- [0244] Minde D P, Maurice M M, Rudiger S G. 2012. Determining biophysical protein stability in lysates by a fast proteolysis assay, FASTpp. *PLoS One* 7: e46147
- [0245] Nyren P, Lundin A. 1985. Enzymatic method for continuous monitoring of inorganic pyrophosphate synthesis. *Anal Biochem* 151: 504-9
- [0246] Pantoliano M W, Petrella E C, Kwasnoski J D, Lobanov V S, Myslik J, et al. 2001. High-density miniaturized thermal shift assays as a general strategy for drug discovery. *J Biomol Screen* 6: 429-40
- [0247] Powell M F, Nguyen T, Baloian L. 1998. Compendium of excipients for parenteral formulations. PDA journal of pharmaceutical science and technology 52: 238-311
- [0248] Quax T E, Claassens N J, Soll D, van der Oost J. 2015. Codon Bias as a Means to Fine-Tune Gene Expression. Mol Cell 59: 149-61
- [0249] Ronaghi M, Uhlen M, Nyren P. 1998. A sequencing method based on real-time pyrophosphate. *Science* 281: 363, 65
- [0250] Rothberg J M, Hinz W, Rearick T M, Schultz J, Mileski W, et al. 2011. An integrated semiconductor device enabling non-optical genome sequencing. *Nature* 475: 348-52
- [0251] Sanger F, Nicklen S, Coulson A R. 1977. DNA sequencing with chain-terminating inhibitors. *Proc Natl* Acad Sci USA 74: 5463-7
- [0252] Semisotnov G V, Rodionova N A, Razgulyaev OI, Uversky V N, Gripas A F, Gilmanshin R I. 1991. Study of the "molten globule" intermediate state in protein folding by a hydrophobic fluorescent probe. *Biopolymers* 31: 119-28 Songsivilai S, Lachmann Pt 1990. Bispecific antibody: a tool for diagnosis and treatment of disease. *Clin Exp Immunol* 79: 315-21
- [0253] Valouev A, Ichikawa J, Tonthat T, Stuart J, Ranade S, et al. 2008. A high-resolution, nucleosome position map of *C. elegans* reveals a lack of universal sequence-dictated positioning. *Genome Res* 18: 1051-63
- [0254] Wu X, Demarest S J. 2018. Building blocks for bispecific and trispecific antibodies. Methods
- [0255] Wu X, Yuan R, Bacica M, Demarest S J. 2018. Generation of orthogonal Fab-based trispecific antibody formats. *Protein Eng Des Sel* 31: 249-56
- [0256] Both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive. The use of the singular includes the plural unless specifically stated otherwise. The use of "or" means "and/or" unless stated otherwise. The use of the term "including", as well as other forms, such as "includes" and "included", is not limiting. Terms such as "element" or "component" encompass both elements and components comprising one unit and elements and compo-